Amyloid-β-Drp1 PPI-IN-1
Amyloid-β-Drp1 PPI-IN-1 is an Amyloid-β-Drp1 protein-protein interaction inhibitor. Amyloid-β-Drp1 PPI-IN-1 inhibits Aβ-Drp1 interaction and decreases Drp1 and Aβ levels. Amyloid-β-Drp1 PPI-IN-1 inhibits excessive mitochondrial fission and promotes mitochondrial fusion and biogenesis. Amyloid-β-Drp1 PPI-IN-1 also alleviates oxidative stress and improves mitochondrial function, and can be used for Alzheimer's disease research.
For research use only. We do not sell to patients.
- CAS No.: 2227449-25-2
- Formula: C22H27N2O5P
- Molecular Weight:430.44
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
Amyloid-β-Drp1 PPI-IN-1 (DDQ) (250 nM; 24 h) decreases Drp1 and Fis1 mRNA by 2.2- and 4.4-fold, respectively, increases Mfn1 and Mfn2 mRNA by 1.7- and 2.3-fold, respectively, and elevates PGC1α, Nrf1, Nrf2, and TFAM expression in SH-SY5Y cells[1].
Amyloid-β-Drp1 PPI-IN-1 (250 nM; 24 h; pretreatment or post-treatment with 20 μM Aβ1-42 exposure) decreases GTPase-Drp1 activity in SH-SY5Y cells and increases SH-SY5Y cell viability[1].
Amyloid-β-Drp1 PPI-IN-1 (250 nM; 24 h; pre- or post-treatment with Aβ1-42 20 μM exposure) reduces the Aβ-Drp1 interaction in SH-SY5Y cells; reduces Aβ-Drp1 colocalization in SH-SY5Y cells[1].
Amyloid-β-Drp1 PPI-IN-1 (250 nM; 24 h) reduces soluble Aβ42 and Aβ40 levels in mutant APPSwe/Ind-N2a cells[1].
Amyloid-β-Drp1 PPI-IN-1 (250 nM; 24 h; pre- or post-treatment with Aβ1-42 20 μM exposure) decreases the mitochondrial number in SH-SY5Y cells; increases the mitochondrial length in SH-SY5Y cells; reduces the mitochondrial H2O2 level in SH-SY5Y cells; decreases the lipid peroxidation level in SH-SY5Y cells; elevates the ATP level in SH-SY5Y cells; and increases the cytochrome oxidase activity in SH-SY5Y cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:SHSY5Y
-
Concentration:250 nM (Amyloid-β-Drp1 PPI-IN-1); 20 μM (Aβ1-42)
-
Incubation Time:24 h (Amyloid-β-Drp1 PPI-IN-1); 6 h (Aβ1-42)
-
Result:Reduced Drp1 and Fis1 protein levels relative to Aβ-exposed cells.
Increased Mfn1/Mfn2 and mitochondrial biogenesis protein levels.
Increased synaptophysin and PSD95 levels.
-
Cell Line:N2a cells expressing mutant APPSwe/Ind
-
Concentration:250 nM
-
Incubation Time:24 h
-
Result:Significantly decreased levels of Aβ42 were found in DDQ treated mutant APPSwe/Ind cells relative to untreated cells.
Aβ40 levels were significantly increased in DDQ treated mutant APPSwe/Ind cells relative to untreated cells.
-
Cell Line:SHSY5Y
-
Concentration:250 nM (Amyloid-β-Drp1 PPI-IN-1); 20 μM (Aβ1-42)
-
Incubation Time:24 h (Amyloid-β-Drp1 PPI-IN-1); 6 h (Aβ1-42)
-
Result:Increased Drp1 levels were found in Aβ treated cells relative to untreated cells.
Decreased Drp1 levels were found in DDQ treated cells relative to untreated cells.
Synaptophysin and PSD95 were significantly reduced in Aβ treated cells.
Significantly reduced levels of Drp1 were found in cells treated with Aβ+DDQ and DDQ+Aβ relative to Aβ treated cells.
Synaptic proteins were increased in Aβ+DDQ and DDQ+Aβ treated cells relative to Aβ treated cells.\nThe immunoreactivity of Drp1 was colocalized with Aβ immunoreactivity in Aβ treated cells.
Reduced co-localization of Drp1 with Aβ was found in DDQ pre-treated and post-treated Aβ incubated cells relative to Aβ incubated cells alone.
The colocalization was markedly reduced in DDQ pre-treated cells than DDQ post-treated cells.
-
Cell Line:SHSY5Y
-
Concentration:250 nM (Amyloid-β-Drp1 PPI-IN-1); 20 μM (Aβ1-42)
-
Incubation Time:24 h (Amyloid-β-Drp1 PPI-IN-1); 6 h (Aβ1-42)
-
Result:Cell viability was significantly increased in cells treated with DDQ compared with untreated cells.
Cell viability levels were unchanged in cells treated with Aβ+DDQ and DDQ+Aβ relative to untreated cells.
Significantly increased cell viability levels were found in cells treated with DDQ+Aβ relative to Aβ incubated cells.
-
Cell Line:SH-SY5Y
-
Concentration:250 nM
-
Incubation Time:24 h
-
Result:Decreased Drp1 mRNA by 2.2-fold.
Decreased Fis1 mRNA by 4.4-fold.
Increased Mfn1 mRNA by 1.7-fold.
Increased Mfn2 mRNA by 2.3-fold.
Increased PGC1α, Nrf1, Nrf2 and TFAM mRNA by 1.5-, 1.9-, 2.7- and 1.7-fold, respectively.
Chemical Information
-
CAS No. 2227449-25-2
-
Molecular Weight 430.44
-
Formula C22H27N2O5P
-
SMILES
O=P(OCC)(OCC)C(NCCC1=CC=C(O)C(O)=C1)C=2C=CN=C3C=CC=CC32
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Mitochondrial membrane-potential fluorescent assay
Mitochondrial membrane potential fluorescent assays estimate ΔΨm in living cells using lipophilic cationic dyes such as TMRM, TMRE, rhodamine 123, and JC-1, which accumulate in mitochondria according to membrane polarization; loss of signal after FCCP or CCCP treatment is interpreted as mitochondrial depolarization. TMRM/TMRE and rhodamine 123 are commonly used for semi-quantitative live-cell microscopy or flow cytometry, while JC-1 can report a shift from red aggregate fluorescence to green monomer fluorescence during depolarization; interpretation requires controls because dye concentration, quenching mode, cell type, dye efflux, and mitochondrial mass can affect fluorescence independently of ΔΨm.
-
Pull-down
The pull-down assay is an in vitro technique used to detect physical interactions between two or more proteins and an invaluable tool for confirming a predicted protein-protein interaction or identifying novel interacting partners. This method typically involves the use of affinity purification with various wash and elution steps.
-
Immunoprecipitation
Immunoprecipitation (IP) is an experimental method that uses the principle of antibody specific binding to purify and enrich target proteins.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Mitochondrial membrane-potential and mitochondrial mass staining
Mitochondrial membrane potential staining measures the electrochemical polarization across the mitochondrial inner membrane in live cells using lipophilic cationic fluorescent probes; early rhodamine-based work showed that selective mitochondrial dye accumulation is lost when the mitochondrial transmembrane potential is dissipated. JC-1 reports mitochondrial polarization by shifting from green monomer fluorescence to red J-aggregate fluorescence as dye concentration increases within energized mitochondria; therefore, the red/green fluorescence ratio is used as a relative readout of mitochondrial membrane potential. TMRE or TMRM staining provides a single-channel relative readout because these cationic rhodamine esters accumulate in polarized mitochondria, and lower fluorescence indicates reduced mitochondrial polarization when acquisition and dye-loading conditions are controlled. Mitochondrial mass staining is commonly performed with MitoTracker Green FM or related MitoTracker dyes as
-
Protocol for Bimolecular Fluorescence Complementation (BiFC) Assay
Bimolecular fluorescence complementation detects protein-protein proximity in living or fixed cells by fusing two candidate interaction partners to nonfluorescent N- and C-terminal fragments of a fluorescent protein; when the partners interact or remain close enough, the fluorescent fragments complement, mature, and generate a fluorescent signal at the site of the protein complex. The BiFC readout is fluorescence intensity and subcellular localization of the reconstituted fluorophore, which reflects formation or stabilization of a protein complex rather than direct biochemical binding kinetics; BiFC is therefore useful for mapping where interactions occur in cancer cells, neurons, macrophages, organoid-derived cells, or drug-screening systems, but results should be validated by independent assays such as co-IP or Western blot. BiFC signal formation is delayed by fluorophore maturation and can stabilize otherwise transient complexes, so it is not a real-time reversible interaction assay
-
Amyloid: Congo Red Amyloid Staining
Congo red amyloid staining is a histochemical method used to detect extracellular amyloid deposits in tissue sections based on the affinity of Congo red dye for β-pleated sheet-rich protein aggregates. When bound to amyloid, Congo red produces characteristic apple-green birefringence under polarized light microscopy, which is widely regarded as a diagnostic feature of amyloid deposition in histopathology. The diagnostic principle relies on the combination of dye binding (congophilia) and optical anisotropy under polarized illumination, which distinguishes amyloid from most non-amyloid eosinophilic extracellular deposits in routine histological evaluation. Amyloid identification by Congo red staining remains a cornerstone in diagnostic pathology despite the availability of adjunct methods such as immunohistochemistry and mass spectrometry, particularly because of its ability to localize deposits directly within tissue architecture. The specificity of Congo red-positive deposits is incre
-
Alzheimer’s Disease Modeling
Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by a progressive decline in cognitive functions and loss of specific types of neurons and synapses. Alzheimer's symptoms can be simulated in mice by injecting drugs (such as Aβ) or genetically modified.
-
Co-Immunoprecipitation
Co-immunoprecipitation technology can verify protein interaction based on the specific immune reaction between antibodies and antigens.
-
Protocol for Yeast Two-Hybrid (Y2H) Assay
The yeast two-hybrid assay detects binary protein-protein interactions by separating a transcription factor into a DNA-binding domain fused to a "bait" protein and a transcriptional activation domain fused to a "prey" protein; if bait and prey interact in yeast, the transcription factor is reconstituted and activates reporter genes such as HIS3, ADE2, lacZ, MEL1, or other selectable/readable reporters. The readout is yeast growth on selective medium and/or reporter activity, which reflects proximity-dependent transcriptional activation in the yeast nucleus rather than direct biochemical binding in the original mammalian, tumor, neuronal, macrophage, or organoid context. Because yeast two-hybrid can generate false positives and false negatives, interaction claims should be validated using independent assays such as co-immunoprecipitation, Western blot, immunofluorescence colocalization, BiFC, pull-down, or mammalian two-hybrid assays.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)